Liu Chuanzhen, Lv Xin, Kong Xiangjin, Meng Lingwei, Wei Kaiming, Wei Ruyuan, Tang Mengmeng, Li Jianhua, Cao Guangqing
Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, Shandong, China; Shandong University, Shandong, China; Pantheum Biotechnology Co., Ltd, Shandong, China.
Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, Shandong, China.
Heart Lung Circ. 2024 Feb;33(2):251-259. doi: 10.1016/j.hlc.2023.11.013. Epub 2024 Feb 1.
Hyperkinetic pulmonary arterial hypertension (PAH) is a complication of congenital heart disease. Gene therapy is a new experimental treatment for PAH, and ultrasound-mediated gene-carrying microbubble targeted delivery is a promising development for gene transfer.
This study successfully established a hyperkinetic PAH rabbit model by a common carotid artery and jugular vein shunt using the cuff style method. Liposome microbubbles carrying the hepatocyte growth factor (HGF) gene were successfully constructed. An in vitro experiment evaluated the appropriate intensity of ultrasonic radiation by Western blots and 3H-TdR incorporation assays. In an in vivo experiment, after transfection of ultrasound-mediated HGF gene microbubbles, catheterisation was applied to collect haemodynamic data. Hypertrophy of the right ventricle was evaluated by measuring the right ventricle hypertrophy index. Western blot and immunohistochemistry analyses were used to detect the expression of human (h)HGF and angiogenic effects, respectively.
The most appropriate ultrasonic radiation intensity was 1.0 W/cm for 5 minutes. Two weeks after transfection, both systolic pulmonary arterial pressure and mean pulmonary arterial pressure were attenuated. Hypertrophy of the right ventricle was reversed. hHGF was transplanted into the rabbits, resulting in a high expression of hHGF protein and an increase in the number of small pulmonary arteries. Ultrasound-mediated HGF gene microbubble therapy was more effective at attenuating PAH and increasing the density of small pulmonary arteries than single HGF plasmid transfection.
Ultrasound-mediated HGF gene microbubbles significantly improved the target of gene therapy in a rabbit PAH model and enhanced the tropism and transfection rates. Thus, the technique can effectively promote small pulmonary angiogenesis and play a role in the treatment of PAH without adverse reactions.
高动力性肺动脉高压(PAH)是先天性心脏病的一种并发症。基因治疗是PAH的一种新型实验性治疗方法,超声介导的载基因微泡靶向递送是基因转移领域一项有前景的进展。
本研究采用套袖法通过颈总动脉与颈静脉分流成功建立了高动力性PAH兔模型。成功构建了携带肝细胞生长因子(HGF)基因的脂质体微泡。体外实验通过蛋白质免疫印迹法和3H-胸腺嘧啶核苷掺入实验评估超声辐射的适宜强度。体内实验中,在转染超声介导的HGF基因微泡后,通过插管收集血流动力学数据。通过测量右心室肥厚指数评估右心室肥厚情况。分别采用蛋白质免疫印迹法和免疫组织化学分析检测人(h)HGF的表达及血管生成效应。
最适宜的超声辐射强度为1.0W/cm,持续5分钟。转染两周后,收缩期肺动脉压和平均肺动脉压均降低。右心室肥厚得到逆转。hHGF被导入兔体内,导致hHGF蛋白高表达以及小肺动脉数量增加。与单纯HGF质粒转染相比,超声介导的HGF基因微泡治疗在减轻PAH和增加小肺动脉密度方面更有效。
超声介导的HGF基因微泡显著改善了兔PAH模型中基因治疗的靶向性,增强了靶向性和转染率。因此,该技术可有效促进小肺动脉血管生成,在PAH治疗中发挥作用且无不良反应。